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INTRODUCTION:  Enoxaparin  prophylaxis  prevents  venous  thromboembolism  in surgical  patients.  Real
time  anti-Factor  Xa  monitoring  for surgical  patients  on enoxaparin  prophylaxis  is  increasingly  common.
PRESENTATION  OF  CASES:  We  report on three  cancer  patients  with  therapeutic  or supratherapeutic  anti-
Factor  Xa  levels  while  on  prophylactic  doses  of  enoxaparin  after  surgical  procedures.  In all  cases,  elevatedvailable online 25 September 2016 anti-Factor  Xa  levels  were  the  result  of blood  specimens  being  removed  from  a  heparinized  chemoport.
DISCUSSION:  This  case  series  highlights  the importance  of  peripheral  venipuncture  or appropriate  blood
wasting  from  central  access  sites  for anti-Factor  Xa  levels.
CONCLUSION:  Inappropriately  drawn  anti-Factor  Xa  levels  may  contribute  to  prophylaxis  interruption  or
unnecessary  workup  for renal  or liver  failure.
©  2016  The  Author(s).  Published  by Elsevier  Ltd on behalf  of  IJS Publishing  Group  Ltd.  This  is  an  open
he CCaccess  article  under  t
. Introduction
Cancer, presence of central venous access, and surgery are rec-
gnized risk factors for venous thromboembolism. Cancer patients
ho have extirpative surgery or reconstructive surgery are com-
only prescribed enoxaparin, a low molecular weight heparin, for
ost-operative VTE prophylaxis [1,2]. Enoxaparin is typically pre-
cribed as a ﬁxed dose among the non-obese population, although
merging literature supports that patient level factors such as larger
xtent of surgical injury and higher gross weight identify patients
ho may  metabolize enoxaparin more quickly [3,4]. Anti-Factor Xa
aFXa) level is a surrogate marker for enoxaparin effectiveness and
afety. aFXa monitoring and individualized enoxaparin dosing is
ncreasingly common for surgical patients who receive enoxaparin
rophylaxis [3–6].
Many cancer patients have residual chemoports after neoadju-
ant chemotherapy. Patients with poor peripheral venous access
ften have these ports accessed for routine medication and ﬂuid
dministration after surgical procedures. In patients with poor
uality veins, labs can also be drawn through the chemoport. Here,
e report on three patients with reported therapeutic or suprather-
∗ Corresponding author.
E-mail address: Christopher.Pannucci@hsc.utah.edu (C.J. Pannucci).
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210-2612/© 2016 The Author(s). Published by Elsevier Ltd on behalf of IJS Publishing 
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
apeutic aFXa levels while on prophylactic doses of enoxaparin as a
result of port-associated unfractionated heparin contamination.
We  are presently enrolling surgical patients into prospective
clinical trials for real time aFXa monitoring and pharmacist driven
enoxaparin dose adjustment at the University of Utah (clinical-
trials.gov identiﬁers NCT02687204 and NCT02704052). Patients
receive a standard dose of enoxaparin and have steady state peak
and trough aFXa levels drawn at 4 and 12 h after the third dose,
respectively. Goal peak aFXa levels for once and twice daily admin-
istration are 0.3–0.5 IU/mL and 0.2–0.4 IU/mL, respectively. Goal
trough levels are 0.1–0.2 IU/mL for both once and twice daily dosing
[7,8]. aFXa levels ≥0.5 IU/mL are considered to represent thera-
peutic anticoagulation [9]. Patients with out of range peak aFXa
levels receive real time dose adjustment to optimize enoxaparin
effectiveness and safety [3,4,6].
2. Presentation of cases
2.1. Case 1
A 45 year old woman with body mass index 31.6 kg/m2 and a
history of breast cancer had a four hour procedure for bilateral tis-
sue expander to implant exchange and pedicled latissimus muscle
ﬂap to cover a radiated tissue expander site. She previously had
neoadjuvant chemotherapy through a tunneled internal jugular
vein chemoport. Subcutaneous enoxaparin 40 mg twice daily was
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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nitiated on post-operative day zero. Steady state peak and trough
FXa were 0.70 IU/mL and >2.00 IU/mL (the upper limit of the test),
espectively. Enoxaparin was discontinued and her creatinine and
iver function tests were demonstrated to be within normal lim-
ts. Twenty four hours after her last enoxaparin dose, aFXa level
as still >2.00 IU/mL. Investigation revealed that the labs had been
rawn from the chemoport instead of peripheral venipuncture. The
ort had been maintained with 100 units of heparin twice daily.
FXa level drawn via peripheral venipuncture at 36 h after last
noxaparin dose was undetectable, and the patient subsequently
ad an in range peak aFXa (0.26 IU/mL) on enoxaparin 30 mg  twice
aily.
.2. Case 2
A 30 year old man  with body mass index 20.1 kg/m2 and a
ediastinal germ cell tumor had a four hour procedure for en
loc resection of a mediastinal mass with a lung wedge resection.
e previously had neoadjuvant chemotherapy through a tunneled
ubclavian vein chemoport. Enoxaparin 40 mg  once daily was ini-
iated on post-operative day one. His baseline creatinine, liver
unction tests, and coagulation parameters were all within nor-
al  limits. Steady state peak aFXa level was drawn via a peripheral
enipuncture and was 0.58 IU/mL. Steady state trough aFXa level
as reported at 1.26 IU/mL. Investigation revealed that his chemo-
ort had been accessed on the day of lab draws and 500 units of
eparin were administered twice daily for line maintenance. The
econd set of labs had been drawn from the heparinized chemoport.
e was discharged prior to repeat labs.
.3. Case 3
A 53 year old woman with a body mass index of 28.2 kg/m2 and
 history of breast cancer had a seven hour procedure for delayed
ight breast reconstruction with a unilateral deep inferior epigas-
ric perforator free ﬂap. She had received adjuvant chemotherapy
hrough a left subclavian chemoport. During surgery, her chemo-
ort was transiently accessed and was then heparinized (dose
nknown) prior to the needle being removed. Enoxaparin 40 mg
wice daily was initiated on post-operative day one. Steady state
FXa was drawn after the third enoxaparin dose through her pre-
iously heparinized chemoport and was 0.71 IU/mL. Steady state
eak and trough aFXa drawn via peripheral venipuncture after her
ourth dose were 0.42 IU/mL and 0.16 IU/mL, respectively. She sub-
equently had an in range peak aFXa (0.38 IU/mL) on enoxaparin
0 mg  twice daily prior to discharge.
. Discussion
Real time monitoring of enoxaparin effectiveness using aFXa
evel is increasingly common among surgical patients [3–6]. This
anuscript provides several important learning points for surgeons
ho plan to monitor aFXa levels. Non-heparinized blood tubes are
equired for aFXa specimens to avoid specimen contamination and
est invalidation [9]. aFXa levels drawn from heparinized central
enous lines, peripherally inserted central catheters, or chemoports
ay  be falsely elevated. These falsely elevated levels may  con-
ribute to unneeded workup for renal or liver failure and may  also
ause unnecessary interruption of enoxaparin prophylaxis. This is
articularly relevant because prophylaxis interruption is associated
ith downstream VTE events [10]. aFXa levels are ideally drawn via
eripheral venipuncture but can theoretically be drawn from cen-
ral venous access if an appropriate volume of blood is wasted prior
o lab collection.PEN  ACCESS
rgery Case Reports 28 (2016) 114–116 115
4. Conclusion
Real time anti-Factor Xa levels are being increasingly used to
optimize enoxaparin prophylaxis in surgery patients. This case
series highlights the importance of appropriate collection of blood
specimens to avoid heparin contamination and falsely elevated
anti-Factor Xa levels.
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